Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity

Blood

Volumn 128, Issue 2, 2016, Pages 195-203

  Lampson, Benjamin L ^a   Kasar, Siddha N ^a   Matos, Tiago R ^a   Morgan, Elizabeth A ^b   Rassenti, Laura ^c,d   Davids, Matthew S ^a,d   Fisher, David C ^a   Freedman, Arnold S ^a   Jacobson, Caron A ^a   Armand, Philippe ^a   Abramson, Jeremy S ^e   Arnason, Jon E ^f   Kipps, Thomas J ^c,d   Fein, Joshua ^a   Fernandes, Stacey ^a,d   Hanna, John ^a   Ritz, Jerome ^a   Kim, Haesook T ^a   Brown, Jennifer R ^a,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IDELALISIB; IMMUNOGLOBULIN HEAVY CHAIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; OFATUMUMAB; PREDNISONE; MONOCLONAL ANTIBODY; PURINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CANCER COMBINATION CHEMOTHERAPY; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COLITIS; CONSTIPATION; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; EDEMA; ENTERITIS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPONATREMIA; HYPOTENSION; INFUSION RELATED REACTION; INSOMNIA; LIVER BIOPSY; LIVER TOXICITY; LUNG INFECTION; LYMPHOCYTIC INFILTRATION; MALE; MONOTHERAPY; MYALGIA; NAUSEA; NIGHT SWEAT; NOSE OBSTRUCTION; ORAL MUCOSITIS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POLYURIA; PRIORITY JOURNAL; RASH; REGULATORY T LYMPHOCYTE; RISK FACTOR; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; XEROSTOMIA; AGE; AUTOIMMUNE HEPATITIS; BLOOD; CLINICAL TRIAL; GENETICS; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LIVER; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; TOXIC HEPATITIS; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CHEMICAL AND DRUG INDUCED LIVER INJURY; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LIVER; MALE; MIDDLE AGED; MUTATION; PURINES; QUINAZOLINONES;

EID: 84978389613     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-03-707133     Document Type: Article

References (37)

1. Sharman JP, Coutre SE, Furman RR, et al. Second interim analysis of a phase 3 study of idelalisib (ZYDELIG) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): Efficacy analysis in patient subpopulations with del (17p) and other adverse prognostic factors [abstract]. Blood. 2014;124 (21). Abstract 330.
2. Coutre SE, Leonard JP, Furman RR, et al. Update on a phase 1 study of the selective PI3K-delta inhibitor, idelalisib (GS-1101) in combination with ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia. Haematologica. 2013;98(suppl 1):1.
3. De Vos S, Leonard JP, Barrientos JC, et al. A phase 1 study of the selective PI3Kd inhibitor idelalisib (GS-1101) in combination with therapeutic anti-CD20 antibodies (rituximab or ofatumumab) in patients with relapsed or refractory chronic lymphocytic leukemia [abstract]. Blood. 2013;122 (21). Abstract 4180.
4. Coutre S, Barrientos JC, Brown JR, et al. Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials. ASCO Meeting Abstracts. 2015;33(15-suppl):e18030.
5. Zelenetz AD, Lamanna N, Kipps TJ, et al. A phase 2 study of idelalisib monotherapy in previously untreated patients $65 years with chronic lymphocytic leukemia or small lymphocytic lymphoma. Paper presented at the Annual Meeting of the American Society of Hematology. December 6, 2014. San Francisco, CA.
6. O'Brien SM, Lamanna N, Kipps TJ, et al. A phase 2 study of idelalisib plus rituximab in treatmentna ïve older patients with chronic lymphocytic leukemia. Blood. 2015;126(25):2686-2694.
7. Okkenhaug K, Bilancio A, Farjot G, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science. 2002;297(5583):1031-1034.
8. Louie CY, DiMaio MA, Matsukuma KE, Coutre SE, Berry GJ, Longacre TA. Idelalisib-associated enterocolitis: Clinicopathologic features and distinction from other enterocolitides. Am J Surg Pathol. 2015;39(12):1653-1660.
9. Weidner AS, Panarelli NC, Geyer JT, et al. Idelalisib-associated colitis: histologic findings in 14 patients. Am J Surg Pathol. 2015;39(12):1661-1667.
10. Coutré SE, Barrientos JC, Brown JR, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56(10):2779-2786.
11. Hallek M, Cheson BD, Catovsky D, et al; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
12. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351(9):893-901.
13. Rassenti LZ, Jain S, Keating MJ, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008;112(5):1923-1930.
14. Ghia EM, Widhopf GF II, Rassenti LZ, Kipps TJ. Analyses of recombinant stereotypic IGHV3-21-encoded antibodies expressed in chronic lymphocytic leukemia. J Immunol. 2011;186(11):6338-6344.
15. Widhopf GF II, Rassenti LZ, Toy TL, Gribben JG, Wierda WG, Kipps TJ. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood. 2004;104(8):2499-2504.
16. Giudicelli V, Chaume D, Jabado-Michaloud J, Lefranc MP. Immunogenetics sequence annotation: The strategy of IMGT based on IMGTONTOLOGY. Stud Health Technol Inform. 2005;116:3-8.
17. Lefranc MP, Giudicelli V, Kaas Q, et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res. 2005;33(Database issue):D593-D597.
18. Baumhoer D, Tzankov A, Dirnhofer S, Tornillo L, Terracciano LM. Patterns of liver infiltration in lymphoproliferative disease. Histopathology. 2008;53(1):81-90.
19. Patton DT, Garden OA, Pearce WP, et al. Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD41CD251Foxp31 regulatory T cells. J Immunol. 2006;177(10):6598-6602.
20. Holt MP, Ju C. Mechanisms of drug-induced liver injury. AAPS J. 2006;8(1):E48-E54.
21. Ajuebor MN, Hogaboam CM, Le T, Proudfoot AE, Swain MG. CCL3/MIP-1alpha is pro-inflammatory in murine T cell-mediated hepatitis by recruiting CCR1-expressing CD4 (1) T cells to the liver. Eur J Immunol. 2004;34(10):2907-2918.
22. Murai M, Yoneyama H, Harada A, et al. Active participation of CCR5 (1) CD8 (1) T lymphocytes in the pathogenesis of liver injury in graft-versushost disease. J Clin Invest. 1999;104(1):49-57.
23. Kitamura K, Farber JM, Kelsall BL. CCR6 marks regulatory T cells as a colon-tropic, IL-10-producing phenotype. J Immunol. 2010;185(6):3295-3304.
24. Soond DR, Bjørgo E, Moltu K, et al. PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood. 2010;115(11):2203-2213.
25. Clayton E, Bardi G, Bell SE, et al. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med. 2002;196(6):753-763.
26. Ali K, Soond DR, Piñeiro R, et al. Inactivation of PI (3) K p110d breaks regulatory T-cell-mediated immune tolerance to cancer. Nature. 2014;510(7505):407-411.
27. Ramsdell F, Ziegler SF. FOXP3 and scurfy: how it all began. Nat Rev Immunol. 2014;14(5):343-349.
28. Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. J Allergy Clin Immunol. 2007;120(4):744-750, quiz 751-752.
29. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110d, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123(22):3390-3397.
30. Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998;92(4):1165-1171.
31. Jin F, Robeson M, Zhou H, et al. Clinical drug interaction profile of idelalisib in healthy subjects. J Clin Pharmacol. 2015;55(8):909-919.
32. Zaborsky N, Holler C, Geisberger R, et al. B-cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD41 T-cell clonality in chronic lymphocytic leukemia. Haematologica. 2015;100(8):e307-e310.
33. Motta M, Rassenti L, Shelvin BJ, et al. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia. 2005;19(10):1788-1793.
34. Weiss L, Melchardt T, Egle A, Grabmer C, Greil R, Tinhofer I. Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. Cancer. 2011;117(10):2163-2169.
35. Burris HA, Patel MR, Fenske TS, et al. TGR-1202, A novel once daily PI3K-delta inhibitor, demonstrates clinical activity with A favorable safety profile, lacking hepatotoxicity, in patients with CLL and B-cell lymphoma. Haematologica. 2015;100(suppl 1):1-3.
36. Mahadevan D, Pauli EK, Cutter K, et al. A phase I trial of TGR-1202, a next generation once daily PI3K-delta inhibitor in combination with obinutuzumab plus chlorambucil, in patients with chronic lymphocytic leukemia [abstract]. Blood. 2015;126 (23). Abstract 2942.
37. Davids MS, Kim HT, Gilbert E, et al. Preliminary results of a phase ib study of duvelisib in combination with FCR (dFCR) in previously untreated, younger patients with CLL [abstract]. Blood. 2015;126 (23). Abstract 4158.